Long Jun, Zhang Shaofang, Fang Xiaoyan, Luo Yuyuan, Liu Jiebo
Department of Pediatrics, Fifth People's Hospital of Shenzhen, Shenzhen, China.
Pediatr Int. 2011 Aug;53(4):530-40. doi: 10.1111/j.1442-200X.2011.03337.x.
Recent reports have suggested that genetic factors, including mutations in the coding region or promoter of uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1) may increase the risk of development of neonatal hyperbilirubinemia, but the relationship has not been evaluated on systematic review or meta-analysis.
A meta-analysis of observational studies reporting effect estimates and 95% confidence intervals (95%CI) was conducted on the association between UGT1A1 polymorphisms and neonatal hyperbilirubinemia.
A total of 27 eligible studies were identified. In total, 17 studies focused on the association of neonatal hyperbilirubinemia with UGT1A1 Gly71Arg polymorphisms, which indicated that these polymorphisms were associated with an increased risk of neonatal hyperbilirubinemia (A/A+G/A vs G/G: odds ratio [OR], 2.70; P= 0.00; 95%CI: 2.22-3.29; I(2) = 0.0%; P(heterogeneity) = 0.55). Subgroup analyses by ethnicity validated this correlation in Asian, but not in Caucasian, populations (OR, 1.74; P= 0.10; 95%CI: 0.90-3.35; I(2) = 0.00%; P(heterogeneity) = 0.67). Furthermore, 18 studies focused on the association of neonatal hyperbilirubinemia with UGT1A1 TATA promoter polymorphisms. These studies concluded that TATA promoter variants were not associated with an increased risk of neonatal hyperbilirubinemia (7/7 + 6/7 vs 6/6: OR, 1.13; P= 0.23; 95%CI: 0.93-1.37; I(2) = 80.0%; P(heterogeneity) = 0.00).
UGT1A1 Gly71Arg polymorphisms are a risk factor for developing neonatal hyperbilirubinemia in Asian, but not Caucasian, subjects. UGT1A1 TATA promoter polymorphisms were not associated with an increased risk of neonatal hyperbilirubinemia in Asian subjects, but results from the Caucasian population were conflicting and require further epidemiological investigation.
最近的报告表明,包括尿苷二磷酸葡萄糖醛酸基转移酶1A1(UGT1A1)编码区或启动子突变在内的遗传因素可能会增加新生儿高胆红素血症的发生风险,但尚未通过系统评价或荟萃分析对这种关系进行评估。
对报告效应估计值和95%置信区间(95%CI)的观察性研究进行荟萃分析,以探讨UGT1A1基因多态性与新生儿高胆红素血症之间的关联。
共纳入27项符合条件的研究。其中,17项研究聚焦于新生儿高胆红素血症与UGT1A1 Gly71Arg基因多态性的关联,结果表明这些多态性与新生儿高胆红素血症风险增加相关(A/A + G/A 对比 G/G:比值比[OR]为2.70;P = 0.00;95%CI:2.22 - 3.29;I² = 0.0%;P(异质性)= 0.55)。按种族进行的亚组分析在亚洲人群中验证了这种相关性,但在白种人群中未得到验证(OR为1.74;P = 0.10;95%CI:0.90 - 3.35;I² = 0.00%;P(异质性)= 0.67)。此外,18项研究聚焦于新生儿高胆红素血症与UGT1A1 TATA启动子多态性的关联。这些研究得出结论,TATA启动子变异与新生儿高胆红素血症风险增加无关(7/7 + 6/7对比6/6:OR为1.13;P = 0.23;95%CI:0.93 - 1.37;I² = 80.0%;P(异质性)= 0.00)。
UGT1A1 Gly71Arg基因多态性是亚洲人群而非白种人群发生新生儿高胆红素血症的危险因素。UGT1A1 TATA启动子多态性与亚洲人群新生儿高胆红素血症风险增加无关,但白种人群的结果存在冲突,需要进一步的流行病学调查。